Capital Stock and Warrants (Narrative) (Details)								1 Months Ended		12 Months Ended
	Sep. 19, 2017 USD ($) shares	May 10, 2017 USD ($) $ / shares shares	Apr. 24, 2017	Nov. 22, 2016 USD ($) $ / shares shares	Jun. 03, 2016 USD ($) $ / shares shares	Apr. 08, 2016 shares	Jan. 04, 2016 USD ($) shares	Sep. 30, 2017 $ / shares shares	May 31, 2017 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) shares	Apr. 30, 2017 $ / shares	Nov. 30, 2016 shares
Class of Stock [Line Items]
Warrants exercised | shares										226,664	0
Warrants forfeited | shares										17,683
Proceeds from exercises of warrants										$ 130,000
Proceeds from equity offerings, net										9,353,000	$ 7,566,000
Conversion ratio of reverse stock split			10
Derivative liability										292,000	2,443,000
Common stock issued pursuant to anti-dilution rights (value)										519,000	1,545,000
Costs related to equity offerings											569,000
Changes in estimated fair value										$ (2,010,000)
Weighted average exercise price of outstanding warrants | $ / shares										$ 2.87
November 2016 Warrant Derivative Liability [Member]
Class of Stock [Line Items]
Number of securities called by warrants | shares													533,500
Exercise price of warrants | $ / shares								$ 0.57
Derivative liability										$ 260,000	$ 2,043,000
Changes in estimated fair value										(1,664,000)
Fair value of warrants issued										$ 260,000
Common Stock Issuance Agreement [Member]
Class of Stock [Line Items]
Number of securities called by warrants | shares						31,519
Common stock issued pursuant to anti-dilution rights (shares) | shares						85,346		523,210
Shares issued per agreement | shares						85,346		523,210
CSIA Second Issuance [Member]
Class of Stock [Line Items]
Common stock issued pursuant to anti-dilution rights (value)	$ 519,000
Number of shares contingently issuable to Holders per CSIA | shares	523,210
Novolytics Ltd [Member]
Class of Stock [Line Items]
Number of securities called by warrants | shares							17,000
Cash consideration for assets acquired							$ 205,000
Novolytics Ltd [Member] | Research and development expense [Member]
Class of Stock [Line Items]
Fair value of assets acquired							409,000
Warrants and rights issued							$ 204,000
Common Stock [Member]
Class of Stock [Line Items]
Common stock issued pursuant to anti-dilution rights (shares) | shares										523,210	75,020
Common stock issued pursuant to anti-dilution rights (value)										$ 5,000	$ 1,000
Shares issued per agreement | shares										523,210	75,020
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Sale of stock, number of shares sold in transaction | shares					212,766
Number of securities called by warrants | shares					106,383
Number of shares called by each warrant | shares					0.50
Sale of stock, price per share | $ / shares					$ 23.50
Proceeds from equity offerings, gross					$ 5,000,000
Exercise price of warrants | $ / shares					$ 22.50
Expiration term of warrants, period following effective date of warrants					5 years
Proceeds from equity offerings, net					$ 4,200,000
Derivative liability										$ 32,000	$ 274,000
Changes in estimated fair value										(242,000)	(1,500,000)
Public Offering of Warrants and Common Stock [Member]
Class of Stock [Line Items]
Sale of stock, number of shares sold in transaction | shares		2,584,085		533,500
Number of securities called by warrants | shares				533,500
Number of shares called by each warrant | shares				1
Sale of stock, price per share | $ / shares				$ 7.50
Proceeds from equity offerings, gross				$ 4,000,000					$ 10,600,000
Exercise price of warrants | $ / shares				$ 7.50				$ 0.57				$ 1.00
Expiration term of warrants, period following effective date of warrants				5 years
Proceeds from equity offerings, net		$ 9,400,000		$ 3,300,000
Derivative liability										260,000	2,000,000
Costs related to equity offerings		$ 1,200,000
Changes in estimated fair value										$ (1,700,000)	$ (886,000)
Public Offering of Warrants and Common Stock [Member] | Common Stock Issuance Agreement [Member]
Class of Stock [Line Items]
Common stock issued pursuant to anti-dilution rights (shares) | shares								523,210
Shares issued per agreement | shares								523,210
Public Offering of Warrants and Common Stock [Member] | Pre-Funded Warrant [Member]
Class of Stock [Line Items]
Number of securities called by warrants | shares		4,483,334
Number of shares called by each warrant | shares		1
Exercise price of warrants | $ / shares		$ 0.01
Combined warrant and stock price per unit | $ / shares		$ 1.49
Public Offering of Warrants and Common Stock [Member] | Common Warrant [Member]
Class of Stock [Line Items]
Number of securities called by warrants | shares		8,000,000
Exercise price of warrants | $ / shares		$ 1.50
Expiration term of warrants, period following effective date of warrants		5 years
Combined warrant and stock price per unit | $ / shares		$ 1.50